Veeva Systems (VEEV): Is the AI Fear Overdone?
- AI is real and disruptive, but in regulated pharma workflows it is more likely to facilitate than replace validated systems overnight.
- Veeva’s moat is rooted in deep pharma/biotech specialization and a unified platform across regulated workflows.
- The clearest competitive threat remains Salesforce Agentforce Life Sciences, especially in commercial CRM.
- Base case is that AI strengthens Veeva more than it displaces it.
DISCLAIMER: This note is intended for US recipients only and, in particular, is not directed at, nor intended to be relied upon by any UK recipients. Any information or analysis in this note is not an offer to sell or the solicitation of an offer to buy any securities. Nothing in this note is intended to be investment advice and nor should it be relied upon to make investment decisions. Read our full disclaimer, here.
The AI Question
by Abhishek Singh
(Note: These are my personal views, blended with some research done using Claude and ChatGPT. There will inevitably be an element of subjectivity in this article, although I have tried to be as objective as possible.)
For those following Veeva and wondering what is happening, this chart (link) shows the YTD performance of VEEV versus Oracle, IQVIA, Salesforce, and the expanded tech-software ETF.
Software stocks have taken a hammering on AI-driven fears. Apparently AI can do everything current software companies do, and all software valuations should be ground to sand. I do not buy that argument. For any given software name, the key question is simple: will AI help drive margin expansion, or will it cause real revenue disruption?
Why AI in Pharma Is Different